|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Nine breast cancers and one ovarian cancer from RAD51C variant carriers were sequenced to identify biallelic inactivation of RAD51C, copy number variation, mutational signatures, and the spectrum of somatic mutations in breast cancer driver genes.
|
30949688 |
2019 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Germline pathogenic variants in BRCA1, BRCA2, PALB2 and RAD51C in breast cancer women from Argentina.
|
31446535 |
2019 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Germline DNA from 1054 BRCA-mutation-negative Hispanic women with hereditary BC (BC diagnosed at age <51 years, bilateral BC, breast and ovarian cancer, or BC diagnosed at ages 51-70 years with ≥2 first-degree or second-degree relatives who had BC diagnosed at age <70 years), 312 local controls, and 887 multiethnic cohort controls was sequenced and analyzed for 12 known and suspected, high-penetrance and moderate-penetrance cancer susceptibility genes (ataxia telangiectasia mutated [ATM], breast cancer 1 interacting protein C-terminal helicase 1 [BRIP1], cadherin 1 [CDH1], checkpoint kinase 2 [CHEK2], nibrin [NBN], neurofibromatosis type 1 [NF1], partner and localizer of BRCA2 [PALB2], phosphatase and tensin homolog [PTEN], RAD51 paralog 3 [RAD51C], RAD51D, serine/threonine kinase 11 [STK11], and TP53).
|
31206626 |
2019 |
|
Breast Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
RAD51C expression was an independent prognostic factor for survival of breast cancer patients.
|
29731842 |
2018 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Pathogenic variants in BRIP1, RAD51C, and TP53 were associated with moderate risk (odds ratio > 2) of TNBC.
|
30099541 |
2018 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
In addition to BRCA1 and BRCA2, RAD51C, PALB2 and BRIP1 are known as breast cancer susceptibility genes.
|
28796317 |
2017 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
CTD_human |
A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer.
|
28825726 |
2017 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Large international collaborative studies are needed to quantify the relative risk of RAD51C alterations for BC and to unravel the genetic modifying factors that determine phenotypic variability with respect to cancer site.
|
27622768 |
2017 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Conversely, variants in the BRIP1 and RAD51C ovarian cancer risk genes; the MRE11A, RAD50, and NBN MRN complex genes; the MLH1 and PMS2 mismatch repair genes; and NF1 were not associated with increased risks of breast cancer.
|
28418444 |
2017 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
RAD51 N(+) and RAD51C(+) tumours were associated with longer and shorter breast cancer-specific survival (BCSS), respectively.
|
27464795 |
2016 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Two components of the complex, RAD51C and RAD51D, increase the risk of ovarian cancer especially, and the other two, RAD51B and XRCC2 have been associated with breast cancer risk.
|
26351136 |
2016 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
These findings provide insight into the mechanism of genomic instability in ERα-positive breast cancer and suggest that individuals with mutations in RAD51C that are exposed to estrogen would be more susceptible to accumulation of DNA damage, leading to cancer progression.
|
27753535 |
2016 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Identification of a breast cancer family double heterozygote for RAD51C and BRCA2 gene mutations.
|
25154786 |
2015 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
RAD51C mutations are predominantly found in families with a history of ovarian cancer and are rare in families with a history of breast cancer alone.
|
25470109 |
2015 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Because of its rising importance in breast cancer development and the lack of information about RAD51C in Slavic populations, our goal was to identify potential population specific mutations in this gene in order to determine more detailed genetic screening strategy and breast cancer risk assessment.
|
26406419 |
2015 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We enrolled 132 unselected BrC females and 189 cancer-free female subjects to investigate whether common single nucleotide polymorphisms (SNPs) in non-coding regions of RAD51C modulate the risk of BrC, and whether they affect the level of oxidative stress and the extent/characteristics of DNA damage.
|
25343521 |
2014 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Our results support that RAD51C is a rare breast and ovarian cancer susceptibility gene and may contribute to a small fraction of families including breast and ovarian cancer cases and families with only breast cancer.
|
25086635 |
2014 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Moreover, a combination of family-based and population-based approaches indicated that genes involved in DNA repair, such as CHEK2, ATM, BRIP1 (FANCJ), PALB2 (FANCN) and RAD51C (FANCO), are associated with moderate BC risk.
|
23747889 |
2013 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our results confirm that RAD51C is a susceptibility gene for ovarian and BC and that this gene should be screened for mutations in families with multiple BC/OC.
|
22725699 |
2013 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
There is ongoing debate whether pathogenic RAD51C alterations increase the relative risk for BC in addition to that for OC, which was estimated to be 5.88 (95% confidence interval = 2.91 to 11.88; P = 7.65 × 10(-7)).
|
24359560 |
2013 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Some of the genes causing the Fanconi anemia (FA) syndrome, such as BRCA2, BRIP1, PALB2, and RAD51C, are associated with high or moderate risk of developing breast cancer.
|
22383991 |
2012 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Distinct roles of FANCO/RAD51C protein in DNA damage signaling and repair: implications for Fanconi anemia and breast cancer susceptibility.
|
22167183 |
2012 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In the Finnish population, we have identified two founder mutations in RAD51C that increase the risk of ovarian cancer but not breast cancer in the absence of ovarian cancer.
|
23176254 |
2012 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Consistent with published results from similar follow-up studies, we suggest that RAD51C mutations are rare events among high-risk breast cancer and breast/ovarian cancer families.
|
22476429 |
2012 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Recent literature reported RAD51C as a new breast cancer susceptibility gene.
|
22370629 |
2012 |